Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.41 |
| ▸ | CA1 | P00915 | 12/20 | 0.41 |
| ▸ | CA2 | P00918 | 12/20 | 0.41 |
| ▸ | CA9 | Q16790 | 12/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | CHAT | P28329 | 2/20 | 0.37 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | PTPRA | P18433 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7778456 | 0.86 | DDX3X (0.46) | CA12CA1CA2CA9RHOA | |
| SCHEMBL14759757 | 0.81 | CA12 (0.42) | CA12CA1CA2CA9SLC16A3 | |
| SCHEMBL7632003 | 0.80 | CA12 (0.40) | CA12CA1CA2CA9TTR | |
| SCHEMBL17562387 | 0.79 | SNCA (0.49) | CA12CA1CA2CA9SNCA | |
| SCHEMBL3657573 | 0.78 | CDK2 (0.45) | CA12CA1CA2CA9SNCA | |
| SCHEMBL22713241 | 0.78 | CA1 (0.36) | CA12CA1CA2CA9SNCA | |
| SCHEMBL15268433 | 0.77 | CA12 (0.55) | CA12CA1CA2CA9 | |
| SCHEMBL9272884 | 0.77 | CA12 (0.42) | CA12CA1CA2CA9SNCA | |
| SCHEMBL28551801 | 0.76 | CA12 (0.40) | CA12CA1CA2CA9SNCA | |
| SCHEMBL7720461 | 0.76 | CDK2 (0.43) | CA12CA1CA2CA9SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183093-B2 | Mannanases | NOVOZYMES A/S (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20030203466-A1 | Mannanases | NOVOZYMES A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203466-A1 | Mannanases | MAN2A1, MANBA, DNASE1L3 | CA12 2608/4885CA1 1654/4885CA2 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.